Abbott Laboratories (ABT) FY2024 Annual Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2024-01-01 to 2024-12-31

Swipe to see the full flow
Abbott Laboratories cash flow reconciliation, Jan 1, 2024 through Dec 31, 2024One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net earnings → Net cash from operating activities: $8,558,000,000.00Net earnings → Operating adjustments reconciliation: $4,844,000,000.00Amortization of intangible assets → Operating adjustments reconciliation: $1,878,000,000.00Depreciation → Operating adjustments reconciliation: $1,340,000,000.00Share-based compensation → Operating adjustments reconciliation: $673,000,000.00Investing and financing losses, net → Operating adjustments reconciliation: $482,000,000.00Trade accounts payable and other liabilities → Operating adjustments reconciliation: $356,000,000.00Operating adjustments reconciliation → Income taxes: $8,028,000,000.00Operating adjustments reconciliation → Prepaid expenses and other assets: $796,000,000.00Operating adjustments reconciliation → Trade receivables: $691,000,000.00Operating adjustments reconciliation → Inventories: $58,000,000.00Proceeds from sales of investment securities → investing reconciliation: $28,000,000.00Other → investing reconciliation: $9,000,000.00Proceeds from business dispositions → investing reconciliation: $1,000,000.00investing reconciliation → Acquisitions of property and equipment: $2,207,000,000.00investing reconciliation → Purchases of investment securities: $169,000,000.00Proceeds from stock options exercised → financing reconciliation: $264,000,000.00Proceeds from issuance of long-term debt and debt with maturities over 3 months → financing reconciliation: $223,000,000.00financing reconciliation → Dividends paid: $3,836,000,000.00financing reconciliation → Purchases of common shares: $1,295,000,000.00financing reconciliation → Repayments of long-term debt and debt with maturities over 3 months: $660,000,000.00financing reconciliation → Proceeds from issuance of (repayments of) short-term debt, net and other: $100,000,000.00Net cash used in financing activities → financing reconciliation: $5,404,000,000.00Net cash used in investing activities → investing reconciliation: $2,338,000,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $6,896,000,000.00Net cash from operating activities → Cash sources and uses: $8,558,000,000.00Cash sources and uses → Exchange-rate effect: $96,000,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $7,616,000,000.00Cash sources and uses → Net cash used in investing activities: $2,338,000,000.00Cash sources and uses → Net cash used in financing activities: $5,404,000,000.00Net earnings: $13,402,000,000.00Net earnings+$13.40 BDepreciation: $1,340,000,000.00Depreciation expense+$1.34 BAmortization of intangible assets: $1,878,000,000.00Intangible amortization+$1.88 BShare-based compensation: $673,000,000.00Stock-based compensation+$673.00 MInvesting and financing losses, net: $482,000,000.00Investing and financing losses, net+$482.00 MTrade receivables: -$691,000,000.00Accounts receivable−$691.00 MInventories: -$58,000,000.00Inventories−$58.00 MPrepaid expenses and other assets: -$796,000,000.00Prepaid & other assets−$796.00 MTrade accounts payable and other liabilities: $356,000,000.00Payables & accrued liabilities+$356.00 MIncome taxes: -$8,028,000,000.00Income taxes payable−$8.03 BNet cash from operating activities: $8,558,000,000.00Operating cash+$8.56 BOperating adjustments reconciliation: $9,573,000,000.00Proceeds from issuance of (repayments of) short-term debt, net and other: -$100,000,000.00Short-term debt, net−$100.00 MProceeds from issuance of long-term debt and debt with maturities over 3 months: $223,000,000.00Proceeds from issuance of long-term debt and debtwith maturities over 3 months+$223.00 MRepayments of long-term debt and debt with maturities over 3 months: -$660,000,000.00Repayments of long-term debt and debt with maturitiesover 3 months−$660.00 MPurchases of common shares: -$1,295,000,000.00Common stock repurchases−$1.30 BProceeds from stock options exercised: $264,000,000.00Stock option exercises+$264.00 MDividends paid: -$3,836,000,000.00Common dividends paid−$3.84 BNet cash used in financing activities: -$5,404,000,000.00. Cash required to fund net payments.Financing cash−$5.40 Bfinancing reconciliation: $5,891,000,000.00Acquisitions of property and equipment: -$2,207,000,000.00PP&E purchases−$2.21 BAcquisitions of businesses and technologies, net of cash acquired: $0.00Proceeds from business dispositions: $1,000,000.00Business & asset sales+$1.00 MPurchases of investment securities: -$169,000,000.00Investment purchases−$169.00 MProceeds from sales of investment securities: $28,000,000.00Other investments sold+$28.00 MOther: $9,000,000.00Other investing, net+$9.00 MNet cash used in investing activities: -$2,338,000,000.00. Cash required to fund net payments.Investing cash−$2.34 Binvesting reconciliation: $2,376,000,000.00Cash sources and uses: $15,454,000,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $6,896,000,000.00Beginning cash$6.90 BEnding cash: Cash, cash equivalents, and restricted cash: $7,616,000,000.00Ending cash$7.62 BExchange-rate effect: -$96,000,000.00FX effect−$96.00 MCASH RECONCILIATIONOperatingflowsInvestingflowsFinancingflowsFree cash flow$6.35 BOperating cash − cash spent on PP&ECash flow / Net income0.64×Operating cash flow ÷ net incomeNet cash change+$720.00 MEnding cash − beginning cash
Chart details

Abbott Laboratories cash flow reconciliation, Jan 1, 2024 through Dec 31, 2024

Cash flows for Jan 1, 2024 through Dec 31, 2024. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2023. Ending cash: Dec 31, 2024. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2023
6,896,000,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
8,558,000,000 US dollars. Net cash provided.
Net earnings
13,402,000,000 US dollars
Depreciation
1,340,000,000 US dollars
Amortization of intangible assets
1,878,000,000 US dollars
Share-based compensation
673,000,000 US dollars
Investing and financing losses, net
482,000,000 US dollars
Trade receivables
negative 691,000,000 US dollars
Inventories
negative 58,000,000 US dollars
Prepaid expenses and other assets
negative 796,000,000 US dollars
Trade accounts payable and other liabilities
356,000,000 US dollars
Income taxes
negative 8,028,000,000 US dollars
Investing activities
negative 2,338,000,000 US dollars. Net cash used.
Acquisitions of property and equipment
negative 2,207,000,000 US dollars
Acquisitions of businesses and technologies, net of cash acquired
0 US dollars
Proceeds from business dispositions
1,000,000 US dollars
Purchases of investment securities
negative 169,000,000 US dollars
Proceeds from sales of investment securities
28,000,000 US dollars
Other
9,000,000 US dollars
Financing activities
negative 5,404,000,000 US dollars. Net cash used.
Proceeds from issuance of (repayments of) short-term debt, net and other
negative 100,000,000 US dollars
Proceeds from issuance of long-term debt and debt with maturities over 3 months
223,000,000 US dollars
Repayments of long-term debt and debt with maturities over 3 months
negative 660,000,000 US dollars
Purchases of common shares
negative 1,295,000,000 US dollars
Proceeds from stock options exercised
264,000,000 US dollars
Dividends paid
negative 3,836,000,000 US dollars
Operating adjustment reconciliation
9,573,000,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
5,891,000,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
2,376,000,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
negative 96,000,000 US dollars
Ending cash on Dec 31, 2024
7,616,000,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
15,454,000,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
720,000,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
0.64×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
8,558,000,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
2,207,000,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
6,351,000,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income exceeds operating cash. The diagram allocates $8.56B of net income directly to operating cash and $4.84B to the adjustment junction, where it combines with other additions to reconcile deductions. This is an accounting presentation, not a tracing of cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 8,558,000,000 US dollars minus 2,207,000,000 US dollars equals 6,351,000,000 US dollars.
Abbott Laboratories (ABT) FY2024 Annual Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!